ﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﺤﻠﻴﺎ ﻤﻥ ﺍﻟﺘﻬﺎﺒﺎﺕ ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻟﺒﻜﺘ K

‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‪ ،‬ﺍﻟﻤﺠﻠﺩ ‪ ،٥١‬ﺍﻟﻌﺩﺩ‪ ،٢٠١٠ ،٣‬ﺍﻟﺼﻔﺤﺔ ‪٤٢١-٤١٥‬‬
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
‫ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻟﺒﻜﺘﺭﻴﺎ ‪ Klebsiella pneumoniae‬ﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﺤﻠﻴﺎ ﻤﻥ ﺍﻟﺘﻬﺎﺒﺎﺕ‬
‫ﺍﻟﻤﺠﺎﺭﻱ ﺍﻟﺒﻭﻟﻴﺔ ﻭﺩﻭﺭﻩ ﻓﻲ ﺍﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﺘﻌﺩﺩﺓ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ‬
‫ﺩﻴﻤﺔ ﻨﺯﺍﺭ ﻓﺭﺝ‪* ،‬ﻗﻴﺱ ﻗﺎﺴﻡ ﻏﻨﻴﻤﺔ‬
‫ﻗﺴﻡ ﻋﻠﻭﻡ ﺍﻟﺤﻴﺎﺓ ‪ ،‬ﻜﻠﻴﺔ ﺍﻟﻌﻠﻭﻡ‪ ،‬ﺠﺎﻤﻌﺔ ﺒﻐﺩﺍﺩ‪ .‬ﺒﻐﺩﺍﺩ‪-‬ﺍﻟﻌﺭﺍﻕ‪.‬‬
‫*ﻤﻌﻬﺩ ﺍﻟﻬﻨﺩﺴﺔ ﺍﻟﻭﺭﺍﺜﻴﺔ ﻭﺍﻟﺘﻘﻨﻴﺎﺕ ﺍﻻﺤﻴﺎﺌﻴﺔ ﻟﻠﺩﺭﺍﺴﺎﺕ ﺍﻟﻌﻠﻴﺎ‪ ،‬ﺠﺎﻤﻌﺔ ﺒﻐﺩﺍﺩ‪ .‬ﺒﻐﺩﺍﺩ‪-‬ﺍﻟﻌﺭﺍﻕ‪.‬‬
‫ﺍﻟﺨﻼﺼﺔ‬
‫ﺩﺭﺴﺕ ﻋﻤﻠﻴﺔ ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻟﺴﺒﻊ ﻋﺯﻻﺕ ﻤﺤﻠﻴﺔ ﻟﺒﻜﺘﺭﻴﺎ ‪ Klebsiella pneumoniae‬ﺍﻟﻤﺘﻌﺩﺩﺓ‬
‫ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﻭﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﻥ ﺤﺎﻻﺕ ﺍﻟﺘﻬﺎﺒﺎﺕ ﺍﻟﻤﺠﺎﺭﻱ ﺍﻟﺒﻭﻟﻴﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻤﺎﺩﺘﻲ ﺍﻟـ ‪Acridin‬‬
‫‪ orange‬ﻭﺍﻟـ ‪.(SDS) Sodium dodecyl sulphate‬‬
‫ﺃﻅﻬﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻥ ﺍﻟﻌﺯﻻﺕ ﺍﻟﻤﺤﻠﻴﺔ ﻟﺠﺭﺜﻭﻤﺔ ‪ K.pneumoniae‬ﻜﺎﻨﺕ ﺫﺍﺕ ﻤﻘﺎﻭﻤﺔ ﻋﺎﻟﻴﺔ ﺠﺩﺍ ًﺍﺫ ﺒﻠﻐﺕ‬
‫)‪ (%100‬ﻟﻤﻀﺎﺩﺍﺕ ﺍﻤﺒﻴﺴﻴﻠﻴﻥ‪،‬ﺒﺒﺭﺍﺴﻴﻠﻴﻥ‪ ،‬ﺍﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ‪ ،‬ﺒﻨﺴﻠﻴﻥ ﺝ‪ ،‬ﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ‪ ،‬ﺍﺭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻭﺠﻨﺘﺎﻤﺎﻴﺴﻴﻥ‬
‫ﻭﺍﻅﻬﺭﺕ ﻤﻘﺎﻭﻤﺔ ﻋﺎﻟﻴﺔ )‪ (%86–71‬ﻟﻤﻀﺎﺩﺍﺕ ﺴﻴﻔﺎﻟﻴﻜﺴﻴﻥ‪ ،‬ﺴﻴﻔﺎﻟﻭﺜﻴﻥ‪ ،‬ﺴﻴﻔﺘﺎﺯﺩﻴﻡ‪ ،‬ﺴﺒﺭﻭﻓﻠﻭﻜﺴﺎﺴﻴﻥ‪،‬‬
‫ﺴﺘﺭﺒﺘﻭﻤﺎﻴﺴﻴﻥ ﻭﺍﻟﺘﻭﺒﺭﺍﻤﺎﻴﺴﻴﻥ‪ ،‬ﻭﻤﻘﺎﻭﻤﺔ ﻤﺘﻭﺴﻁﺔ )‪ (%57–43‬ﻟﻤﻀﺎﺩﺍﺕ ﺴﻴﻔﺎﻜﻠﻭﺭ‪ ،‬ﺴﻴﻔﺭﺍﺩﻴﻥ‪ ،‬ﻭﻨﺎﻟﺩﻜﺴﻙ‬
‫ﺍﺴﻴﺩ‪ ،‬ﻓﻲ ﺤﻴﻥ ﺍﻨﻬﺎ ﺍﻅﻬﺭﺕ ﻤﻘﺎﻭﻤﺔ ﻀﻌﻴﻔﺔ )‪ (%29‬ﻟﻤﻀﺎﺩ ﺴﻴﻔﻭﺘﺎﻜﺴﻴﻡ ﻭﺍﻨﻬﺎ ﻜﺎﻨﺕ ﺤﺴﺎﺴﺔ ﻟﻤﻀﺎﺩﺍﺕ‬
‫ﻜﻠﻭﺭﺍﻤﻔﻴﻨﻴﻜﻭل ﻭﺍﻤﻴﻜﺎﺴﻴﻥ‪.‬‬
‫ﻭﻤﻥ ﺨﻼل ﻋﻤﻠﻴﺔ ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻭﺠﺩ ﺍﻥ ﻤﺎﺩﺓ ﺍﻟـ ‪ SDS‬ﺍﻜﺜﺭ ﻜﻔﺎﺀﺓ ﻓﻲ ﺍﺤﺩﺍﺙ ﺍﻟﺘﺤﻴﻴﺩ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟـ‬
‫‪ orange Acridine‬ﺤﻴﺙ ﻟﻭﺤﻅ ﻓﻘﺩﺍﻥ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠـ ‪ SDS‬ﺒﻤﺩﻯ )‪–70‬‬
‫‪ (%100‬ﺍﻤﺎ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠـ‪ Acridine‬ﻓﻜﺎﻨﺕ )‪ ،(%100–28‬ﻭﺒﻌﺩ ﻋﻤﻠﻴﺔ ﺍﻟﺘﺤﻴﻴﺩ ﻓﻘﺩﺕ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻤﻀﺎﺩﺍﺕ‬
‫ﺍﻟﺒﺒﺭﺍﺴﻴﻠﻴﻥ‪ ،‬ﺍﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ‪ ،‬ﺒﻨﺴﻠﻴﻥ ﺝ‪ ،‬ﺴﻴﻔﺎﻟﻴﻜﺴﻴﻥ‪ ،‬ﺴﻴﻔﺎﻟﻭﺜﻴﻥ‪،‬ﺴﻴﻔﺘﺎﺯﺩﻴﻡ‪ ،‬ﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ‪ ،‬ﺠﻨﺘﺎﻤﺎﻴﺴﻴﻥ‬
‫ﻭﺘﻭﺒﺭﺍﻤﺎﻴﺴﻴﻥ ﻤﻤﺎ ﻴﺩل ﻋﻠﻰ ﺍﻥ ﺼﻔﺔ ﻤﻘﺎﻭﻤﺔ ﻫﺫﻩ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﻤﺤﻤﻭﻟﺔ ﻋﻠﻰ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻓﻲ ﺤﻴﻥ ﻟﻡ ﺘﻔﻘﺩ‬
‫ﻤﻘﺎﻭﻤﺔ ﻤﻀﺎﺩﺍﺕ ﺍﻻﻤﺒﻴﺴﻴﻠﻴﻥ‪ ،‬ﺴﺒﺭﻭﻓﻠﻭﻜﺴﺎﺴﻴﻥ‪ ،‬ﺍﺭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻭﺴﺘﺭﺒﺘﻭﻤﺎﻴﺴﻴﻥ ﻤﻤﺎ ﻴﺩل ﻋﻠﻰ ﺍﻥ ﺍﻟﻤﻭﺭﺜﺎﺕ‬
‫ﺍﻟﺘﻲ ﺘﺸﻔﺭ ﻟﻤﻘﺎﻭﻤﺘﻬﺎ ﻤﺤﻤﻭﻟﺔ ﻋﻠﻰ ﺍﻟﻜﺭﻭﻤﻭﺴﻭﻡ‪.‬‬
‫‪PLASMID CURING OF LOCAL ISOLATES OF KLEBSIELLA‬‬
‫‪PNEUMONIAE ISOLATED FROM URINARY TRACT‬‬
‫‪INFECTIONS AND ITS ROLE IN MULTIDRUG RESISTANCE‬‬
‫*‪Dimah Nazar Faraj, Kais Kassim Ghanima‬‬
‫‪Department of Biology, College of Science, University of Baghdad.‬‬
‫‪* Institute of Genetic Engineering and Biotechnology for Postgraduate Studies, University of Baghdad‬‬
‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‪ ،‬ﺍﻟﻤﺠﻠﺩ ‪ ،٥١‬ﺍﻟﻌﺩﺩ‪ ،٢٠١٠ ،٣‬ﺍﻟﺼﻔﺤﺔ ‪٤٢١-٤١٥‬‬
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
‫‪Abstract‬‬
‫‪Curing of plasmid for 7 local isolates of K. pneumoniae have multi-drug resistance‬‬
‫‪and isolated from urinary tract infections (UTI) by using acridin orange and sodium‬‬
‫‪dodecyl sulphate (SDS) were investigated.‬‬
‫‪These results showed that the local isolates of K. pneumoniae were very resist‬‬
‫‪(100%) to Ampicillin, Pepracillin, Amoxicillin, Penicillin G, Tetracyclin,‬‬
‫‪Erythromycin and Gentamycin, high resist (71–80%) to Cephalexin, Cephalothin,‬‬
‫‪Ceftazidine, Ciprofloxacin, Streptomycin and Tobramycin, moderate resist‬‬
‫‪(43–57%) to Cefaclor, Cephradin and Naldixic acid and weak resist (29%) to‬‬
‫‪Cefotaxime while they were susceptible to Chloramphenicol and Amikacin.‬‬
‫‪t was found that SDS is more efficient in curing than Acridin orange, hence the‬‬
‫)‪losing of the resistance of antibiotics by using SDS was in the range (70–100%‬‬
‫‪while by using Acridin orange was in the range (28– 100%). After curing of plasmid‬‬
‫‪the Antibiotics resistance losed for Pipracillin, Amoxicillin, Penicillin G,‬‬
‫‪Cephalexin, Cephalothin, Ceftazidin, Tetracyclin, Gentamycin and Tobramycin, this‬‬
‫‪result confirm that the resistance of these antibiotics is born on plasmid, while the‬‬
‫‪resistance of Ampicillin, Ciprofloxacin, Erythromycin and Streptomycin not losed,‬‬
‫‪this result confirm that there resistance genes are born on the chromosome.‬‬
‫ﺍﻟﻤﻘﺩﻤﺔ‬
‫ﺘﻌﺩ ﺒﻜﺘﺭﻴﺎ ‪ Klebsiella pneumoniae‬ﻤﻥ ﺍﻟﻌﺼـﻴﺎﺕ‬
‫ﺍﻟﻤﻤﺭﻀﺔ ﺍﻟﺴﺎﻟﺒﺔ ﻟﺼﺒﻐﺔ ﻜﺭﺍﻡ ﺍﻨﺘﻬﺎﺯﻴﺔ ﻟﻠﻔﺭﺹ ﺘﺴـﺎﻫﻡ ﻓـﻲ‬
‫ﺍﺤﺩﺍﺙ ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺍﺼﺎﺒﺎﺕ ﺍﻟﺠﻬﺎﺯ ﺍﻟﺘﻨﻔﺴﻲ ﺍﻟﺴﻔﻠﻲ ﻭﺍﻟﻤﺠـﺎﺭﻱ‬
‫ﺍﻟﺒﻭﻟﻴﺔ ﻭﺍﺼﺎﺒﺎﺕ ﺍﻟﺠﺭﻭﺡ ﻭﺍﻟﺤﺭﻭﻕ ]‪ ،[١‬ﻭﻫﺫﻩ ﺍﻟﺒﻜﺘﺭﻴﺎ ﺘـﺄﺘﻲ‬
‫ﺒﺎﻟﻤﺭﺘﺒﺔ ﺍﻟﺜﺎﻨﻴﺔ ﻤﻥ ﻤﺴﺒﺒﺎﺕ ﺍﻟﺘﻬﺎﺒﺎﺕ ﺍﻟﻤﺠﺎﺭﻱ ﺍﻟﺒﻭﻟﻴـﺔ ﺒﻌـﺩ‬
‫ﺒﻜﺘﺭﻴﺎ ﺍﻟـ ‪.[2] Escherichia coli‬‬
‫ﺘﺤﻭﻱ ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺍﻟﻌﺼﻴﺎﺕ ﺍﻟﺴﺎﻟﺒﺔ ﻟﺼﺒﻐﺔ ﻜـﺭﺍﻡ ﺒﻼﺯﻤﻴـﺩﺍﺕ‬
‫ﺘﺤﻤل ﻤﻭﺭﺜـﺎﺕ ﺍﻟﻤﻘﺎﻭﻤـﺔ ﻟﻤﻀـﺎﺩﺍﺕ ﺍﻻﻤﻴﻨﻭﻜﻼﻴﻜﻭﺴـﺎﻴﺩ‪،‬‬
‫ﺍﻟﻜﻠﻭﺭﺍﻤﻔﻴﻨﻜﻭل‪ ،‬ﺍﻟﺴﻠﻔﻭﻨﺎﻤﺎﻴﺩ‪ ،‬ﺍﻟﺘﺭﺍﻴﻤﻴﺜﻭﺒﺭﻴﻡ ﻭﺍﻟﺘﺘﺭﺍﺴـﺎﻴﻜﻠﻴﻥ‪،‬‬
‫ﻭﻓﻲ ﺍﻨﻭﺍﻉ ﺒﻜﺘﺭﻴﺎ ﺍﻟـ ‪ Klebsiella‬ﺘﻭﺠﺩ ﺍﻨﻭﺍﻉ ﻤﺨﺘﻠﻔﺔ ﻤـﻥ‬
‫ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﺍﻟﺘﻲ ﺘﺸﻔﺭ ﻻﻨﺯﻴﻤﺎﺕ ﺍﻟﺒﻴﺘﺎﻻﻜﺘﺎﻤﻴﺯ ﻭﺍﺴﻌﺔ ﺍﻟﻁﻴﻑ‬
‫ﺍﻟﻤﺴﺅﻭﻟﺔ ﻋﻥ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺒﻴﺘﺎ ﻻﻜﺘﺎ ]‪ ،[٣‬ﻭﺍﻟﺠـﺭﺍﺜﻴﻡ‬
‫ﺍﻟﻤﺘﻌﺩﺩﺓ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﻋﺎﺩﺓ ﻤـﺎﺘﺤﻭﻱ ﺠﻴﻨـﺎﺕ‬
‫ﻗﺎﻓﺯﺓ ﻤﺘﻌﺩﺩﺓ ﻭﺒﻼﺯﻤﻴﺩﺍﺕ ﺘﺤﻤل ﻤﺤﺩﺩﺍﺕ ﻭﺭﺍﺜﻴﺔ ﻟﻤﻴﻜﺎﻨﻴﻜﻴـﺎﺕ‬
‫ﻤﺨﺘﻠﻔﺔ ﻤﻥ ﺍﻟﻤﻘﺎﻭﻤﺔ ﺘﺠﻌل ﻤﻥ ﻋﻤﻠﻴﺔ ﺍﻟﻌﻼﺝ ﺒﺎﻟﻤﻀﺎﺩﺍﺕ ﺼﻌﺒﺔ‬
‫ﺠﺩﹰﺍ ﻭﻗﺩ ﻴﻘﻭﺩ ﺫﻟﻙ ﺍﻟﻰ ﺍﺴﺘﺨﺩﺍﻡ ﻤﻀـﺎﺩﺍﺕ ﻭﺍﺴـﻌﺔ ﺍﻟﻁﻴـﻑ‬
‫ﺒﺎﻫﻀﺔ ﺍﻟﺜﻤﻥ ]‪ [4‬ﻭﻴﻤﻜﻥ ﻟﺨﻼﻴﺎ ﺍﻟﺒﻜﺘﺭﻴﺎ ﺍﻥ ﺘﻔﻘﺩ ﺍﻟﺒﻼﺯﻤﻴـﺩﺍﺕ‬
‫ﺘﻠﻘﺎﺌﻴﹰﺎ ﻭﻟﻜﻥ ﺒﺘﺭﺩﺩﺍﺕ ﻭﺍﻁﺌﺔ ﻭﻫﺫﻩ ﺍﻟﻅـﺎﻫﺭﺓ ﺘﺴـﻤﻰ ﺍﻟﺘﺤﻴﻴـﺩ‬
‫ﺍﻟﺘﻠﻘﺎﺌﻲ ﻭﺒﺎﻻﻤﻜﺎﻥ ﺯﻴﺎﺩﺓ ﺘﺭﺩﺩ ﻓﻘﺩﺍﻥ ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﻋﻨﺩ ﺘﻌﺭﺽ‬
‫ﺍﻟﺨﻼﻴﺎ ﺍﻟﻰ ﻤﺭﻜﺒﺎﺕ ﺘﺤﺸﺭ ﻨﻔﺴﻬﺎ ﺒـﻴﻥ ﻗﻭﺍﻋـﺩ ﺍﻟــ ‪DNA‬‬
‫ﻭﺒﺸﻜل ﺨﺎﺹ ﺍﻻﻜﺭﺩﻴﻨﺎﺕ ﻤﺜل ﺍﻟــ ‪Ethidium bromide‬‬
‫ﻭﺍﻟـ ‪ Acridine‬ﺍﻭ ﺒﺎﺴـﺘﺨﺩﺍﻡ ﻤـﻭﺍﺩ ﻤﺜـل ﺍﻟــ )‪(SDS‬‬
‫‪.[5] Sodium dodecyl sulphate‬‬
‫ﺍﺴﺘﻬﺩﻓﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺤﺼﻭل ﻋﻠﻰ ﻋﺯﻻﺕ ﻤﺤﻠﻴﺔ ﻟﺒﻜﺘﺭﻴـﺎ‬
‫‪ Klebsiella pneumoniae‬ﻤﻥ ﻋﻴﻨﺎﺕ ﺍﻟﺘﻬﺎﺒﺎﺕ ﺍﻟﻤﺠـﺎﺭﻱ‬
‫ﺍﻟﺒﻭﻟﻴﺔ ﻭﺘﺸﺨﻴﺼﻬﺎ ﻭﺩﺭﺍﺴﺔ ﻤﻘﺎﻭﻤﺘﻬﺎ ﻟﻤﺠﻤﻭﻋﺔ ﻤﺨﺘـﺎﺭﺓ ﻤـﻥ‬
‫ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ‪ ،‬ﻭﺍﻟﻌﻼﻗﺔ ﺒـﻴﻥ ﻫـﺫﻩ ﺍﻟﻤﻘﺎﻭﻤـﺔ ﻭﻭﺠـﻭﺩ‬
‫ﺍﻟﺒﻼﺯﻤﻴﺩ ﻋﻥ ﻁﺭﻴﻕ ﺍﺠﺭﺍﺀ ﻋﻤﻠﻴﺔ ﺍﻟﺘﺤﻴﻴـﺩ ﻟﻠﺒﻼﺯﻤﻴـﺩ ﻓـﻲ‬
‫ﻋﺯﻻﺕ ﻫﺫﻩ ﺍﻟﺒﻜﺘﺭﻴﺎ ﺒﺎﺴـﺘﺨﺩﺍﻡ ﺒﻌـﺽ ﺍﻟﻌﻭﺍﻤـل ﺍﻟﻜﻴﻤﻴﺎﺌﻴـﺔ‬
‫ﻭﻤﻘﺎﺭﻨﺔ ﺍﻟﻨﺘﺎﺌﺞ‪.‬‬
‫ﺍﻟﻤﻭﺍﺩ ﻭﻁﺭﺍﺌﻕ ﺍﻟﻌﻤل‬
‫ﺍﻟﻌﺯل ﻭﺍﻟﺘﺸﺨﻴﺹ‬
‫ﺠﻤﻌﺕ ‪ 150‬ﻋﻴﻨﺔ ﻤﻥ ﻋﻴﻨﺎﺕ ﺍﻟﺒﻭل )ﻟﻠﻨﺴﺎﺀ ﻭﺍﻟﺭﺠﺎل ﻤﻥ‬
‫ﻋﻤﺭ ‪ 50 –20‬ﺴﻨﺔ( ﻤﻥ ﻤﺴﺘﺸﻔﻰ ﺍﻟﻜﻨﺩﻱ ﺍﻟﺘﻌﻠﻴﻤﻲ ﺨﻼل ﺍﻟﻤﺩﺓ‬
‫ﻤﻥ ﺸﻬﺭ ﻜﺎﻨﻭﻥ ﺍﻟﺜﺎﻨﻲ ﺍﻟﻰ ﺸﻬﺭ ﻨﻴﺴﺎﻥ ﻟﻠﻌﺎﻡ ‪ 2007‬ﻓﻲ ﺍﻭﻋﻴﺔ‬
‫ﺒﻼﺴﺘﻴﻜﻴﺔ ﻤﻌﻘﻤﺔ ﻭﺯﺭﻋﺕ ﻤﺒﺎﺸﺭﺓ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﺎﻗل ﺯﺭﻉ ﻤﻌﻘـﻡ‬
‫ﻋﻠﻰ ﺍﻭﺴﺎﻁ ﺍﻜﺎﺭ ﺍﻟﺩﻡ ﻭﺍﻜﺎﺭ ﻤﺎﻜﻭﻨﻜﻲ )ﺍﻟﻤﺠﻬﺯﺓ ﻤـﻥ ﺸـﺭﻜﺔ‬
‫‪ Himedia‬ﺍﻟﻬﻨﺩﻴﺔ( ﻭﺤﻀﻨﺕ ﻋﻨﺩ ﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ ‪ 37°‬ﻡ ﻟﻤـﺩﺓ‬
‫‪ 24‬ﺴﺎﻋﺔ ﻭﺸﺨﺼﺕ ﺍﻟﺒﻜﺘﺭﻴـﺎ ﺒﺎﻻﻋﺘﻤـﺎﺩ ﻋﻠـﻰ ﺍﻟﺼـﻔﺎﺕ‬
‫ﺍﻟﺘﺸﺨﻴﺼﻴﺔ ﺍﻟﺨﺎﺼﺔ ﺒﺎﻟﺒﻜﺘﺭﻴﺎ ]‪ [٧ ،٦‬ﻭﻟﻠﺘﺄﻜـﺩ ﻤـﻥ ﺼـﺤﺔ‬
‫ﺍﻟﺘﺸﺨﻴﺹ ﺘﻡ ﺍﺴﺘﺨﺩﺍﻡ ﻨﻅﺎﻡ ﺍﻟﺘﺸﺨﻴﺹ ‪.API-20E‬‬
‫ﺍﺨﺘﺒﺎﺭ ﺍﻟﺤﺴﺎﺴﻴﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﺎﺘﻴﺔ‬
‫ﺍﺴﺘﺨﺩﻤﺕ ﻁﺭﻴﻘﺔ ﺍﻻﻨﺘﺸﺎﺭ ﻋﻠﻰ ﺴﻁﺢ ﺍﻜﺎﺭ ﻤﻭﻟﺭ‪ -‬ﻫﻨﺘﻭﻥ‬
‫)ﺍﻟﻤﺠﻬﺯﻤﻥ ﺸﺭﻜﺔ ‪ Himedia‬ﺍﻟﻬﻨﺩﻴﺔ( ﺒﺎﺴـﺘﺨﺩﺍﻡ ﺍﻻﻗـﺭﺍﺹ‬
‫)‪ [8] (Disc-diffusion method‬ﻻﺨﺘﺒﺎﺭ ﺤﺴﺎﺴﻴﺔ ﺒﻜﺘﺭﻴـﺎ‬
‫‪ K.Pneumaniae‬ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺤﻴـﺙ ﻟﻘـﺢ ﺍﻟﻭﺴـﻁ‬
‫ﺒﺎﺴﺘﺨﺩﺍﻡ ﻤﺴﺤﺔ ﻗﻁﻨﻴﺔ ﻤﻥ ﻟﻘﺎﺡ ﻋﺩﺩ ﺍﻟﺨﻼﻴﺎ ﺍﻟﺠﺭﺜﻭﻤﻴـﺔ ﻓﻴـﻪ‬
‫‪ ١٠٨ × ١.٥‬ﺨﻠﻴﺔ ‪ /‬ﻤﻠﻠﺘﺭ ﻭﻭﻀـﻌﺕ ﺍﻗـﺭﺍﺹ ﺍﻟﻤﻀـﺎﺩﺍﺕ‬
‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‪ ،‬ﺍﻟﻤﺠﻠﺩ ‪ ،٥١‬ﺍﻟﻌﺩﺩ‪ ،٢٠١٠ ،٣‬ﺍﻟﺼﻔﺤﺔ ‪٤٢١-٤١٥‬‬
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
‫ﺍﻟﺤﻴﻭﻴﺔ ﻭﺤﻀﻨﺕ ﺍﻻﻁﺒﺎﻕ ﺒﺩﺭﺠﺔ ﺤـﺭﺍﺭﺓ ‪ ْ 37‬ﻡ ﻟﻤـﺩﺓ ‪24‬‬
‫ﺍﻋﻭﺍﺩ ﺨﺸﺒﻴﺔ ﻭﺒﻁﺭﻴﻘﺔ )‪ (Pickand Patch‬ﺍﻟﻰ ﺍﻁﺒـﺎﻕ ﻤـﻥ‬
‫ﺴﺎﻋﺔ‪ .‬ﻭﻴﻭﻀـﺢ ﺍﻟﺠـﺩﻭل ‪ ١‬ﺍﻨـﻭﺍﻉ ﺍﻟﻤﻀـﺎﺩﺍﺕ ﺍﻟﺤﻴﺎﺘﻴـﺔ‬
‫ﺍﻻﻜﺎﺭ ﺍﻟﻤﻐﺫﻱ ﺍﻟﺤﺎﻭﻱ ﻋﻠﻰ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﻪ ﻗﻴﺩ ﺍﻟﺩﺭﺍﺴـﺔ‬
‫ﺒﺎﻟـ ‪ µg / ml‬ﻭﺍﻟﺸﺭﻜﺔ ﺍﻟﻤﺼﻨﻌﺔ ﻟﻬﺎ‪.‬‬
‫ﺍﻟﺒﻜﺘﺭﻴﺎ ﻭﺤﻀﻨﺕ ﺍﻻﻁﺒﺎﻕ ﻋﻨﺩ ﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ ‪ °37‬ﻡ ﻟﻤﺩﺓ ‪24‬‬
‫ـﺎ‬
‫ـﺘﺨﺩﻤﺔ ﻭﺘﺭﺍﻜﻴﺯﻫــــــــــ‬
‫ﺍﻟﻤﺴــــــــــ‬
‫ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺼﺒﻐﺔ ﺍﻟـ ‪Acridine‬‬
‫‪orange‬‬
‫ﺍﺘﺒﻌﺕ ﻁﺭﻴﻘﺔ ‪ [9] Trevors‬ﻓﻲ ﻤﻌﺎﻤﻠﺔ ﻋﺯﻻﺕ ﺒﻜﺘﺭﻴـﺎ‬
‫‪ K.pneumoniae‬ﺒﻭﺴﺎﻁﺔ ﺼﺒﻐﺔ ﺍﻟــ ‪Acridine orange‬‬
‫)ﺍﺫ ﺘﻡ ﺍﺨﺘﻴﺎﺭ ﺘﺭﻜﻴﺯ ﺍﻟﺼﺒﻐﺔ ﺍﻟﺘﻲ ﺴﺒﻘﺕ ﺍﻟﺘﺭﻜﻴﺯ ﺍﻟﻤﺜﺒﻁ ﺍﻻﺩﻨﻰ‬
‫ﻻﺨﺘﺒﺎﺭ ﺍﻟﺘﺤﻴﻴﺩ ﻭﺍﻟﻤﺘﻤﺜل ﺒﺎﻟﺘﺭﻜﻴﺯ ‪ 120 µg/ml‬ﻭﺍﻟﺘﻲ ﻴﻜـﻭﻥ‬
‫ﻋﺩﺩ ﺍﻟﺨﻼﻴﺎ ﺍﻟﺤﻲ ﺍﻗﺭﺏ ﺍﻟﻰ ﺍﻟﺴﻴﻁﺭﺓ ﻏﻴﺭ ﺍﻟﻤﻌﺎﻤﻠﺔ(‪.‬‬
‫ﺠﺩﻭل ‪:١‬ﺍﺴﻤﺎﺀ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺍﻟﻤﺴﺘﺨﺩﻤﺔ ﻭﺘﺭﻜﻴﺯﻫﺎ ﻭﺍﻟﺸﺭﻜﺔ‬
‫ﺍﻟﻤﺼﻨﻌﺔ ﻟﻬﺎ‪.‬‬
‫ﺍﺴﻡ ﺍﻟﻤﻀﺎﺩ‬
‫‪code‬‬
‫ﺘﺭﻜﻴﺯﻩ‬
‫‪µg/ml‬‬
‫ﺍﻟﺸﺭﻜﺔ‬
‫ﺍﻟﻤﺼﻨﻌﺔ‬
‫‪Ampicillin‬‬
‫‪Pepracillin‬‬
‫‪Amoxicillin‬‬
‫‪Penicillin G‬‬
‫‪Cephalexin‬‬
‫‪Cephalothin‬‬
‫‪Cefaclor‬‬
‫‪Cephradine‬‬
‫‪Cefotaxime‬‬
‫‪Cephtazidine‬‬
‫‪Ciprofloxacin‬‬
‫‪Tetracyclin‬‬
‫‪Chloramphenicol‬‬
‫‪Erythromycin‬‬
‫‪Gentamicin‬‬
‫‪Streptomycin‬‬
‫‪Tobramycin‬‬
‫‪Nalidixic acid‬‬
‫‪Amikacin‬‬
‫‪AM‬‬
‫‪PRL‬‬
‫‪AX‬‬
‫‪P‬‬
‫‪CI‬‬
‫‪CF‬‬
‫‪CEC‬‬
‫‪CE‬‬
‫‪CTX‬‬
‫‪CTZ‬‬
‫‪CIP‬‬
‫‪TE‬‬
‫‪C‬‬
‫‪E‬‬
‫‪G‬‬
‫‪S‬‬
‫‪Tob‬‬
‫‪NA‬‬
‫‪AK‬‬
‫‪10‬‬
‫‪100‬‬
‫‪25‬‬
‫‪10‬‬
‫‪30‬‬
‫‪30‬‬
‫‪30‬‬
‫‪30‬‬
‫‪30‬‬
‫‪30‬‬
‫‪10‬‬
‫‪30‬‬
‫‪10‬‬
‫‪15‬‬
‫‪50‬‬
‫‪26‬‬
‫‪30‬‬
‫‪30‬‬
‫‪10‬‬
‫‪AL-Razi‬‬
‫‪AL-Razi‬‬
‫‪AL-Razi‬‬
‫‪AL-Razi‬‬
‫‪Oxoid‬‬
‫‪Oxoid‬‬
‫‪Oxoid‬‬
‫‪Oxoid‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Oxoid‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Bioanalyse‬‬
‫‪Oxoid‬‬
‫ﺠﻬﺯ ﻫﺫﺍ ﺍﻟﺘﺭﻜﻴﺯ ﻓﻲ ‪ 5‬ﻤﻠﻠﺘﺭ ﻤﻥ ﺍﻟﻤﺭﻕ ﺍﻟﻤﻐﺫﻱ ﻭﺘﺭﻙ ﺍﻨﺒﻭﺏ‬
‫ﻤﻥ ﺩﻭﻥ ﺍﻀﺎﻓﺔ ﺍﻟﺼﺒﻐﺔ ﻜﺴﻴﻁﺭﺓ ﻭﻟﻘﺤﺕ ﺍﻻﻨﺎﺒﻴﺏ ﺒﺤﻭﺍﻟﻲ‪104‬‬
‫ﺨﻠﻴﺔ ‪ /‬ﻤﻠﻠﺘﺭ ﻭﺤﻀﻨﺕ ﺒﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ ‪ °37‬ﻡ ﻟﻤﺩﺓ ‪ 24‬ﺴـﺎﻋﺔ‬
‫ﺜﻡ ﻋﻤﻠﺕ‬
‫ﺘﺨﺎﻓﻴﻑ ﻟﺠﻤﻴﻊ ﺍﻟﻤﺯﺍﺭﻉ ﺍﻟﻤﻌﺎﻤﻠﺔ ﻭﺍﻟﺴﻴﻁﺭﺓ ﻏﻴـﺭ‬
‫ﺍﻟﻤﻌﺎﻤﻠﺔ ﺤﻴﺙ ﺨﻔﻑ ﺍﻟﻤﺯﺭﻭﻉ ﺍﻟﻰ ‪ 10-7 ،10-6 ،10-5‬ﻭﻨﺸـﺭ‬
‫ﻤﻘﺩﺍﺭ ‪ 0.2‬ﻤﻠﻠﺘﺭ ﻋﻠﻰ ﻭﺴﻁ ﺍﻻﻜﺎﺭ ﺍﻟﻤﻐﺫﻱ ﺍﻟﺼﻠﺏ ﻭﺤﻀـﻥ‬
‫ﺒﺩﺭﺠﺔ ﺤـﺭﺍﺭﺓ ‪ °37‬ﻡ ﻟﻤـﺩﺓ ‪ 24‬ﺴـﺎﻋﺔ ﺍﻭ ﺤﺘـﻰ ﻅﻬـﻭﺭ‬
‫ﻤﺴﺘﻌﻤﺭﺍﺕ ﻭﺍﻀﺤﺔ‪ ،‬ﺒﻌﺩﻫﺎ ﺘﻡ ﻨﻘل ‪ 100‬ﻤﺴـﺘﻌﻤﺭﺓ ﺒﻭﺴـﺎﻁﺔ‬
‫)ﻭﺒﻨﻔﺱ ﺍﻟﺘﺭﺍﻜﻴﺯ ﺍﻟﻤﺴﺘﺨﺩﻤﺔ ﻓﻲ ﺍﻻﻗﺭﺍﺹ( ﻭﺍﻟﺘـﻲ ﻗﺎﻭﻤﺘﻬـﺎ‬
‫ﺴﺎﻋﺔ ﻭﺘﻡ ﻤﻼﺤﻅﺔ ﺍﻟﻨﺘﺎﺌﺞ ﻭﻟﻐﺭﺽ ﺍﻟﺘﻌـﺭﻑ ﻋﻠـﻰ ﺍﻟﺨﻼﻴـﺎ‬
‫ﺍﻟﻤﺤﻴﺩﺓ ﻓﺎﻨﻨﺎ ﻨﻼﺤﻅ ﻋﺩﻡ ﻅﻬﻭﺭ ﻨﻤﻭ ﻋﻠـﻰ ﻭﺴـﻁ ﺍﻟﻤﻀـﺎﺩ‬
‫ﻭﻅﻬﻭﺭﻩ ﻋﻠﻰ ﺍﻟﻭﺴﻁ ﺍﻟﺨﺎﻟﻲ ﻤﻥ ﺍﻟﻤﻀﺎﺩ ﻭﻫﺫﺍ ﻴﻌﻨﻲ ﺍﻥ ﺍﻟﺨﻠﻴﺔ‬
‫ﻓﻘﺩﺕ ﺼﻔﺔ ﻤﻘﺎﻭﻤﺔ ﺫﻟﻙ ﺍﻟﻤﻀﺎﺩ‪.‬‬
‫ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﺒﺎﺴﺘﺨﺩﺍﻡ ‪Sodium dodecyl‬‬
‫‪(SDS) sulphate‬‬
‫ﺍﺘﺒﻌﺕ ﻁﺭﻴﻘﺔ ‪ Marcelo‬ﻭﺠﻤﺎﻋﺘﻪ ]‪ [10‬ﻓـﻲ ﻤﻌﺎﻤﻠـﺔ‬
‫ﻋﺯﻻﺕ ﺒﻜﺘﺭﻴﺎ ‪ K. pneumoniae‬ﺒﻭﺴﺎﻁﺔ ﺍﻟـ ‪ SDS‬ﺤﻴـﺙ‬
‫ﺘﻡ ﺍﺨﺘﻴﺎﺭ ﺍﻟﺘﺭﻜﻴﺯ )‪ ،(%1‬ﻟﻘﺢ ‪ 5‬ﻤﻠﻠﺘﺭ ﻤـﻥ ﻭﺴـﻁ ﺍﻟﻤـﺭﻕ‬
‫ﺍﻟﻤﻐﺫﻱ ﺒﻤﺴﺘﻌﻤﺭﺓ ﻤﻥ ﺒﻜﺘﺭﻴﺎ ‪ K. pneumoniae‬ﻭﺤﻀﻥ ﻋﻨﺩ‬
‫ﺩﺭﺠﺔ ‪ 37‬ﻡ ﻟﻤﺩﺓ ‪ 24‬ﺴﺎﻋﺔ ﺜﻡ ﻟﻘﺢ ‪ 5‬ﻤﻠﻠﺘﺭ ﻤﻥ ﻭﺴﻁ ﺍﻟﻤـﺭﻕ‬
‫ﺍﻟﻤﻐﺫﻱ ﺍﻟﺤﺎﻭﻱ ﻋﻠﻰ ﺍﻟـ ‪ SDS‬ﺒﺘﺭﻜﻴﺯ ﻨﻬﺎﺌﻲ ‪ %١‬ﺒﺤـﻭﺍﻟﻲ‬
‫‪ 104‬ﺨﻠﻴﺔ‪/‬ﻤﻠﻠﺘﺭ ﻤﻥ ﺍﻟﻤﺯﺭﻋﺔ ﺍﻟﺠﺭﺜﻭﻤﻴﺔ ﺍﻟﻤﺤﻀـﺭﺓ ﻤﺴـﺒﻘﹰﺎ‬
‫ﻭﺤﻀﻨﺕ ﺍﻻﻨﺎﺒﻴﺏ ﻋﻨﺩ ﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ‬
‫‪ 37‬ﻡ ﻟﻤﺩﺓ ‪ 24‬ﺴـﺎﻋﺔ‬
‫ﻭﺘﺭﻙ ﺍﻨﺒﻭﺏ ﺩﻭﻥ ﺍﻀﺎﻓﺔ ﻤﺎﺩﺓ ‪ SDS‬ﻜﺴـﻴﻁﺭﺓ‪ .‬ﺒﻌـﺩ ﺫﻟـﻙ‬
‫ﺍﺠﺭﻴﺕ ﺴﻠﺴﻠﺔ ﻤـﻥ ﺍﻟﺘﺨـﺎﻓﻴﻑ ﻟﺠﻤﻴـﻊ ﺍﻟﻤـﺯﺍﺭﻉ ﺍﻟﻤﻌﺎﻤﻠـﺔ‬
‫ﻭﺍﻟﺴﻴﻁﺭﺓ ﻏﻴﺭ ﺍﻟﻤﻌﺎﻤﻠﺔ ﺤﻴﺙ ﺨﻔﻑ ﺍﻟﻤﺯﺭﻭﻉ ﺍﻟﻰ ‪10-6 ،10-5‬‬
‫ﻭ ‪ 10-7‬ﻭﻨﺸﺭ ﻤﻘﺩﺍﺭ ‪ 0.2‬ﻤﻠﻠﺘﺭ ﻋﻠﻰ ﻭﺴﻁ ﺍﻻﻜـﺎﺭ ﺍﻟﻤﻐـﺫﻱ‬
‫ﺍﻟﺼﻠﺏ ﻭﺤﻀﻥ ﺒﺩﺭﺠﺔ ﺤﺭﺍﺭﺓ ‪37‬ﻡ ﻟﻤﺩﺓ ‪ 24‬ﺴﺎﻋﺔ ﺍﻭ ﺤﺘـﻰ‬
‫ﻅﻬﻭﺭ ﻤﺴﺘﻌﻤﺭﺍﺕ ﺒﺸﻜل ﻭﺍﻀﺢ ﻭﺒﻌﺩﻫﺎ ﺘﻜﻤل ﺍﻟﺘﺠﺭﺒﺔ ﻜﻤﺎ ﻓﻲ‬
‫ﻁﺭﻴﻘﺔ ﺍﻟﺘﺤﻴﻴﺩ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺼﺒﻐﺔ ﺍﻟـ‪.Acridine orange‬‬
‫ﺍﻟﻨﺘﺎﺌﺞ ﻭﺍﻟﻤﻨﺎﻗﺸﺔ‬
‫ﻤﻥ ﻤﺠﻤﻭﻉ ‪ 150‬ﻋﻴﻨﺔ ﻤـﻥ ﻋﻴﻨـﺎﺕ ﺍﻟﺒـﻭل ﻟﻤﺭﻀـﻰ‬
‫ﻤﺼﺎﺒﻴﻥ ﺒﺎﻟﺘﻬﺎﺒﺎﺕ ﺍﻟﻤﺠﺎﺭﻱ ﺍﻟﺒﻭﻟﻴﺔ ﻜﺎﻨﺕ ‪ 110‬ﻋﻴﻨﺔ ﻤﻭﺠﺒـﺔ‬
‫ﻟﻅﻬﻭﺭ ﺍﻟﻨﻤﻭ ﺍﻟﺒﻜﺘﻴﺭﻱ ﻭﻤﻥ ﻫﺫﻩ ﺍﻟﻌﻴﻨﺎﺕ ﺘﻡ ﺍﻟﺤﺼﻭل ﻋﻠﻰ ‪23‬‬
‫ﻋﺯﻟﺔ ﻤﺤﻠﻴﺔ ﻟﻠﺠﻨﺱ ‪ Klebsiella‬ﺍﻱ ﺒﻨﺴﺒﺔ ﻋـﺯل ‪،%25.9‬‬
‫‪ 12‬ﻤﻨﻬﺎ ﺘﻌﻭﺩ ﺍﻟﻰ ﺍﻟﻨﻭﻉ ‪ Klebsiella pneumoniae‬ﻭﺒﻨﺴﺒﺔ‬
‫ﻋﺯل ‪ ،%10.9‬ﺍﻋﺘﻤﺎﺩﹰﺍ ﻋﻠﻰ ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﺍﻟﺘﺸﺨﻴﺼﻴﺔ ﺍﻟﺨﺎﺼﺔ‬
‫ﺒﻬﺫﻩ ﺍﻟﺠﺭﺜﻭﻤﺔ ]‪ [٧ ،٦‬ﻜﻤﺎ ﺘﻡ ﺍﻟﺘﺄﻜﺩ ﻤﻥ ﺼـﺤﺔ ﺍﻟﺘﺸـﺨﻴﺹ‬
‫ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﻅﺎﻡ ﺍﻟﺘﺸﺨﻴﺹ )‪.(API-20E‬‬
‫ﺘﻡ ﺍﺠﺭﺍﺀ ﺍﺨﺘﺒﺎﺭ ﺍﻟﺤﺴﺎﺴﻴﺔ ﻟﻠﻌﺯﻻﺕ ﺍﻟﻤﺤﻠﻴﺔ ﻗﻴﺩ ﺍﻟﺩﺭﺍﺴﺔ ﻟﻌﺩﺩ‬
‫ﻤﻥ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺍﺫ ﻟﻭﺤﻅ ﻓﻲ ﺍﻻﺨﺘﺒﺎﺭ ﺍﻻﻭﻟﻲ ﻟﺤﺴﺎﺴﻴﺔ‬
‫ﺍﻟﻌﺯﻻﺕ ﺍﻟﺠﺭﺜﻭﻤﻴﺔ ﻟـ ‪ 19‬ﻤﻀﺎﺩ ﺤﻴـﻭﻱ ﺍﻤﺘﻠﻜـﺕ ﺴـﺒﻌﺔ‬
‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‪ ،‬ﺍﻟﻤﺠﻠﺩ ‪ ،٥١‬ﺍﻟﻌﺩﺩ‪ ،٢٠١٠ ،٣‬ﺍﻟﺼﻔﺤﺔ ‪٤٢١-٤١٥‬‬
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
‫ﻋﺯﻻﺕ ﻤﻘﺎﻭﻤﺔ ﻤﺘﻌﺩﺩﺓ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ )‪Multi- (MDR‬‬
‫]‪،[13,12‬ﻜﻤﺎ ﻗﺩ ﻴﻌﻭﺩ ﺴﺒﺏ ﺍﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻌﺎﻟﻴﺔ ﻟﻬﺫﻩ ﺍﻟﻤﻀـﺎﺩﺍﺕ‬
‫‪ Resistant drug‬ﺍﻱ ﺍﻨﻬﺎ ﻤﻘﺎﻭﻤﺔ ﻟﺜﻼﺙ ﻤﻀﺎﺩﺍﺕ ﺍﻭ ﺍﻜﺜـﺭ‬
‫ﺍﻟﻰ ﺍﻥ ﻫﺫﻩ ﺍﻟﻌﺯﻻﺕ ﻏﺎﻟﺒﹰﺎ ﻤﺎ ﺘﻌﻭﺩ ﺍﻟـﻰ ﻤﺭﻀـﻰ ﺍﺴـﺘﻌﻤﻠﻭﺍ‬
‫ﻭﻴﺘﻀﺢ ﻤﻥ ﺍﻟﺠﺩﻭل ‪ 2‬ﺍﻥ ﻫﻨﺎﻟـﻙ ﺍﺨﺘﻼﻓـﺎﺕ ﺒﺴـﻴﻁﺔ ﺒـﻴﻥ‬
‫ﺍﻥ ﺘﻌﺩﺩ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻤﺠﺎﻤﻴﻊ ﻤﻔﻴﺩﺓ ﻤﻥ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺘﺸﻤل‬
‫ﺍﻟﻌﺯﻻﺕ ﻓﻲ ﻤﻘﺎﻭﻤﺘﻬﺎ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﻭﺍﻨﻬﺎ ﻤﻘﺎﻭﻤـﺔ ﺠـﺩﹰﺍ‬
‫ﺍﻟﺒﺘﺎﻻﻜﺘﺎﻡ‪ ،‬ﺍﻻﻤﻴﻨﻭﻜﻼﻴﻜﻭﺴﺎﻴﺩ ﻭﺍﻟﻜﻭﻴﻨﻭﻟـﻭﻨﺯ ﻗـﺩ ﺍﺯﺩﺍﺩ ﻓـﻲ‬
‫)‪ (%100‬ﻟﻤﻀﺎﺩﺍﺕ ﺍﻻﻤﺒﻴﺴﻠﻴﻥ‪ ،‬ﺒﺒﺭﺍﺴـﻴﻠﻴﻥ‪ ،‬ﺍﻤﻭﻜﺴﻴﺴـﻴﻠﻴﻥ‪،‬‬
‫ﺍﻟﺴﻨﻭﺍﺕ ﺍﻻﺨﻴﺭﺓ ﺒﺸﻜل ﻋﺎﻡ ﺒﻴﻥ ﻋﺩﺩ ﻤـﻥ ﺍﻟﺒﻜﺘﺭﻴـﺎ ﺍﻟﺴـﺎﻟﺒﺔ‬
‫ﺒﻨﺴﻠﻴﻥ ﺝ‪ ،‬ﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ‪ ،‬ﺍﺭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻭﺠﻨﺘﺎﻤﺎﻴﺴﻴﻥ‪ .‬ﻭﺍﻅﻬﺭﺕ‬
‫ﻟﺼﺒﻐﺔ ﻜﺭﺍﻡ ﺨﺎﺼﺔ ﺒﻴﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺭﺍﻗﺩﻴﻥ ﻓﻲ ﺍﻟﻤﺴﺘﺸـﻔﻴﺎﺕ‬
‫ﺍﻟﻌﺯﻻﺕ ﻤﻘﺎﻭﻤﺔ ﻋﺎﻟﻴﺔ ﻟﻤﻀﺎﺩﺍﺕ ﺴﻴﻔﺎﻟﻴﻜﺴـﻴﻥ‪ ،‬ﺴـﻴﻔﺎﻟﻭﺜﻴﻥ‪،‬‬
‫]‪ [14‬ﻭﻓﻲ ﺍﻟﺩﻭل ﺍﻟﻨﺎﻤﻴﺔ ﺘﻜﻭﻥ ﻤﻘﺎﻭﻤﺔ ﺍﻟﺒﻜﺘﺭﻴـﺎ ﻟﻠﻤﻀـﺎﺩﺍﺕ‬
‫ﺴﻴﻔﺘﺎﺯﺩﻴﻡ‪ ،‬ﺴﺒﺭﻭﻓﻠﻭﻜﺴﺎﺴﻴﻥ‪ ،‬ﺴﺘﺭﺒﺘﻭﻤﺎﻴﺴﻴﻥ ﻭﺍﻟﺘﻭﺒﺭﺍﻤﺎﻴﺴـﻴﻥ‬
‫ﻋﺎﻟﻴﺔ ﻭﻫﺫﺍ ﻤﺭﺘﺒﻁ ﺒﺎﻻﺴﺘﻌﻤﺎل ﻏﻴﺭ ﺍﻟﻤﻨﺎﺴﺏ ﻟﻬﺫﻩ ﺍﻟﻤﻀـﺎﺩﺍﺕ‬
‫ـﻴﻔﺎﻜﻠﻭﺭ‪،‬‬
‫ـﺎﺩﺍﺕ ﺴـ‬
‫ـﻁﺔ ﻟﻤﻀـ‬
‫ـﺔ ﻤﺘﻭﺴـ‬
‫)‪ ،(%86–71‬ﻭﻤﻘﺎﻭﻤـ‬
‫ﻭﻓﻘﺩﺍﻥ ﺍﻟﻌﻨﺎﻴﺔ ﺍﻟﺼﺤﻴﺔ ﺍﻟﺸﺨﺼﻴﺔ ﻭﺍﺴـﺘﻌﻤﺎل ﻋﻼﺠـﺎﺕ ﺫﺍﺕ‬
‫ﺴﻴﻔﺭﺍﺩﻴﻥ ﻭﻨﺎﻟﺩﻜﺴﻙ ﺍﺴﻴﺩ )‪ ،(%57–43‬ﻓﻲ ﺤﻴﻥ ﺍﻨﻬﺎ ﺍﻅﻬﺭﺕ‬
‫ﻨﻭﻋﻴﺔ ﺭﺩﻴﺌﺔ ﻭﻫﺫﺍ ﻤﺎ ﻴﺠﻌل ﻋﻤﻠﻴﺔ ﺍﻟﻌﻼﺝ ﺼﻌﺒﻪ ]‪.[15‬‬
‫ﻤﻘﺎﻭﻤﺔ ﻀﻌﻴﻔﺔ ﻟﻤﻀﺎﺩ ﺴﻴﻔﻭﺘﺎﻜﺴﻴﻡ )‪ (%29‬ﻭﻜﺎﻨـﺕ ﺤﺴﺎﺴـﺔ‬
‫ﺘﻅﻬﺭ ﺍﻟﺠﺭﺍﺜﻴﻡ ﺍﻟﻤﻨﺘﺠﺔ ﻻﻨﺯﻴﻤﺎﺕ ﺍﻟﺒﻴﺘﺎﻻﻜﺘﺎﻤﻴﺯ ﺤﺴﺎﺴﻴﺔ ﻟﺒﻌﺽ‬
‫ﻟﻤﻀﺎﺩﺍﺕ ﻜﻠﻭﺭﺍﻤﻔﻨﻴﻜﻭل ﻭﺍﻻﻤﻴﻜﺎﺴﻴﻥ‪.‬‬
‫ﺍﻟﻤﻀﺎﺩﺍﺕ ﻤﺜل ﺍﻻﻤﻴﻜﺎﺴﻴﻥ ]‪ [16‬ﻜﻤﺎ ﻟﻭﺤﻅ ﺍﻥ ﻤﻌﻅﻡ ﻋﺯﻻﺕ‬
‫ﻤﻥ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﻤﺴﺘﺨﺩﻤﺔ ﻭﻜﻤﺎ ﻤﻭﻀﺢ ﻓﻲ ﺍﻟﺠﺩﻭل ‪.2‬‬
‫ﺟﺪول ‪ :2‬اﺧﺘﺒﺎر اﻟﺤﺴﺎﺳﻴﺔ ﻟﻠﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ ﻟﻌﺰﻻت‬
‫‪[11] . K.pneumoniae‬‬
‫ﻋﺩﺩ ﻋﺯﻻﺕ ‪K. pneumoniae‬‬
‫ﺍﻟﻨﺴﺒﺔ‬
‫ﺕ‬
‫‪1‬‬
‫‪2‬‬
‫‪3‬‬
‫‪4‬‬
‫‪5‬‬
‫‪6‬‬
‫‪7‬‬
‫‪8‬‬
‫‪9‬‬
‫‪10‬‬
‫‪11‬‬
‫‪12‬‬
‫‪13‬‬
‫‪14‬‬
‫‪15‬‬
‫‪16‬‬
‫‪17‬‬
‫‪18‬‬
‫‪19‬‬
‫‪:R‬‬
‫ﺍﻟﻤﻀﺎﺩ ﺍﻟﺤﻴﻭﻱ‬
‫‪K7 K6 K5 K4 K3 K2 K1‬‬
‫‪R‬‬
‫‪Ampicillin‬‬
‫‪R‬‬
‫‪Pepracillin‬‬
‫‪R‬‬
‫‪Amoxicillin‬‬
‫‪R‬‬
‫‪Penicillin G‬‬
‫‪R‬‬
‫‪Cephalexin‬‬
‫‪I‬‬
‫‪Cephalothin‬‬
‫‪S‬‬
‫‪Cefaclor‬‬
‫‪S‬‬
‫‪Cephradine‬‬
‫‪S‬‬
‫‪Cefotaxime‬‬
‫‪S‬‬
‫‪Ceftazidine‬‬
‫‪R Ciprofloxacin‬‬
‫‪R‬‬
‫‪Tetracyilin‬‬
‫‪S Chloramphenicol‬‬
‫‪R Erythromycin‬‬
‫‪R‬‬
‫‪Gentamycin‬‬
‫‪R Streptomycin‬‬
‫‪I‬‬
‫‪Tobramycin‬‬
‫‪R Nalidixic acid‬‬
‫‪S‬‬
‫‪Amikacin‬‬
‫‪ :S‬ﺤﺴﺎﺴﺔ‬
‫ﻤﻘﺎﻭﻤﺔ‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R I R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R I‬‬
‫‪R R R‬‬
‫‪R R I‬‬
‫‪R R R‬‬
‫‪S S S‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪I R R‬‬
‫‪R R R‬‬
‫‪R R S‬‬
‫‪S S S‬‬
‫‪ :I‬ﻤﺘﻭﺴﻁ‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪I R R‬‬
‫‪R I R‬‬
‫‪I R I‬‬
‫‪S I R‬‬
‫‪S I I‬‬
‫‪I R R‬‬
‫‪I R R‬‬
‫‪R R R‬‬
‫‪S I S‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪R R R‬‬
‫‪I S S‬‬
‫‪S S S‬‬
‫ﺍﻟﺤﺴﺎﺴﻴﺔ‬
‫ﺍﻟﻤﺌﻭﻴﺔ‬
‫ﻟﻠﻌﺯﻻﺕ‬
‫ﺍﻟﻤﻘﺎﻭﻤﺔ‬
‫‪100%‬‬
‫‪100%‬‬
‫‪100%‬‬
‫‪100%‬‬
‫‪71%‬‬
‫‪71%‬‬
‫‪57%‬‬
‫‪57%‬‬
‫‪29%‬‬
‫‪71%‬‬
‫‪71%‬‬
‫‪100%‬‬
‫‬‫‪100%‬‬
‫‪100%‬‬
‫‪86%‬‬
‫‪86%‬‬
‫‪43%‬‬
‫‪-‬‬
‫ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺍﻟﻤﻀﺎﺩﺍﺕ ﻭﻟﻤﺩﺓ ﺯﻤﻨﻴﻪ ﻁﻭﻴﻠﺔ ]‪ .[12‬ﻤﻥ ﺍﻟﻭﺍﻀـﺢ‬
‫‪ K. pneumoniae‬ﺍﻟﻤﻨﺘﺠـﺔ ﻟﻠــ ‪ ESBL‬ﻜﺎﻨـﺕ ﻤﻘﺎﻭﻤـﺔ‬
‫ﻟﻠﺠﻨﺘﺎﻤﺎﻴﺴﻴﻥ ﻭﺍﻟﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﻭﻟﻜﻨﻬـﺎ ﺤﺴﺎﺴـﺔ ﻟﻠﺴﻴﻔﻭﻜﺴـﻴﺘﻴﻥ‬
‫ﻭﺍﻻﻤﻴﻜﺎﺴﻴﻥ ]‪ .[17‬ﻭﺍﻟﺤﺴﺎﺴﻴﺔ ﺍﻟﺘﻲ ﺍﻅﻬﺭﺘﻬﺎ ﺍﻟﻌﺯﻻﺕ ﺍﻟﻤﺤﻠﻴﺔ‬
‫ﻟﻠﻜﻠﻭﺭﺍﻤﻔﻨﻴﻜﻭل ﻗﺩ ﻴﻌﻭﺩ ﺍﻟﻰ ﻗﻠﺔ ﺍﺴﺘﺨﺩﺍﻡ ﻫﺫﺍ ﺍﻟﻤﻀﺎﺩ ﻟﻌـﻼﺝ‬
‫ﺍﺼﺎﺒﺎﺕ ﺍﻟـ ‪.[18] UTI‬‬
‫ﺘﻡ ﺍﺠﺭﺍﺀ ﺘﺠﺭﺒـﺔ ﺍﻟﺘﺤﻴﻴـﺩ ﻟﻠﺒﻼﺯﻤﻴـﺩﺍﺕ ﺒﺎﺴـﺘﺨﺩﺍﻡ ﺍﻟــ‬
‫‪ Acridine orange‬ﻭﺍﻟـ ‪ SDS‬ﻋﻠﻰ ﺠﻤﻴـﻊ ﻋـﺯﻻﺕ ‪K.‬‬
‫‪ pneumoniae‬ﻭﺍﺨﺘﺒﺎﺭ ﺤﺴﺎﺴﻴﺔ ﺍﻟﺒﻜﺘﺭﻴﺎ ﺘﺠﺎﻩ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺘﻲ‬
‫ﺍﻅﻬﺭﺕ ﻟﻬﺎ ﻤﻘﺎﻭﻤﺔ ﻋﺎﻟﻴﺔ ﻭﻜﻤﺎ ﻫﻭ ﻤﻭﻀﺢ ﻤﻥ ﺍﻟﺠـﺩﻭﻟﻴﻥ ‪3‬‬
‫ﻭ‪.4‬‬
‫ﺠﺩﻭل ‪ :3‬ﺘﺄﺜﻴﺭ ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻟﻌﺯﻻﺕ ‪K. pneumoniae‬‬
‫ﺒﺎﺴﺘﺨﺩﺍﻡ ‪ Acridine orange‬ﻓﻲ ﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ‪.‬‬
‫ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﻟﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﺍﻟﺫﻱ‬
‫ﺕ‬
‫‪1‬‬
‫ﻴﺸﻔﺭ ﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﻀﺎﺩ )‪(%‬‬
‫ﺍﻟﻤﻀﺎﺩ ﺍﻟﺤﻴﺎﺘﻲ‬
‫ﺭﻗﻡ ﻋﺯﻟﺔ ‪K. pneumoniae‬‬
‫‪K7 K6 K5 K4 K3 K2 K1‬‬
‫‪R R R R R R 10 Ampicillin‬‬
‫‪2‬‬
‫‪Pepracillin‬‬
‫‪66 45 79 80 42 85 50‬‬
‫‪92 94 90‬‬
‫‪85‬‬
‫‪3‬‬
‫‪Amoxicillin‬‬
‫‪S‬‬
‫‪S‬‬
‫‪4‬‬
‫‪Penicillin G‬‬
‫‪S‬‬
‫‪89 93 95 90‬‬
‫‪5‬‬
‫‪Cephalexin‬‬
‫‪78 80‬‬
‫‪I‬‬
‫‪S‬‬
‫‪S‬‬
‫‪67 81 60‬‬
‫‪95‬‬
‫‪I‬‬
‫ﺍﻥ ﺍﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻌﺎﻟﻴﺔ ﺍﻟﺘﻲ ﺍﻅﻬﺭﺘﻬﺎ ﺒﻜﺘﺭﻴـﺎ ‪K. pneumoniae‬‬
‫‪6‬‬
‫‪Cephalothin‬‬
‫‪I‬‬
‫‪70 69 28 40‬‬
‫ﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺒﻴﺘﺎﻻﻜﺘﺎﻡ ﺘﻌﻭﺩ ﺒﺸﻜل ﻜﺒﻴﺭ ﺍﻟﻰ ﺍﻨﺘﺎﺠﻬﺎ ﻻﻨﺯﻴﻤـﺎﺕ‬
‫‪7‬‬
‫‪Ceftazidine‬‬
‫‪S‬‬
‫‪75 90 71 80 81‬‬
‫‪I‬‬
‫‪R Ciprofloxacin 8‬‬
‫‪R‬‬
‫‪I‬‬
‫ﺍﻟﺒﺘﺎﻻﻜﺘﺎﻤﻴﺯ ﻭﺍﺴﻌﺔ ﺍﻟﻁﻴﻑ – ‪Extended Spectrum Beta‬‬
‫)‪(ESBL‬‬
‫‪ Lactamase‬ﺍﺫ ﺍﺸﺎﺭﺕ ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺎﺕ ﺍﻟﻰ‬
‫ﺍﻥ ﺍﻨﻭﺍﻉ ﺍﻟـ ‪ Klebsiella‬ﻤﻨﺘﺠﺔ ﺒﺸﻜل ﻜﺒﻴﺭ ﻟﻬﺫﻩ ﺍﻻﻨﺯﻴﻤﺎﺕ‬
‫‪9‬‬
‫‪Tetracyilin‬‬
‫‪I‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪I‬‬
‫‪77‬‬
‫‪S‬‬
‫‪85 66 88 83 87 90‬‬
‫‪R Erythromycin 10‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪86 84 69 79 72 91 70 Gentamycin 11‬‬
‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‪ ،‬ﺍﻟﻤﺠﻠﺩ ‪ ،٥١‬ﺍﻟﻌﺩﺩ‪ ،٢٠١٠ ،٣‬ﺍﻟﺼﻔﺤﺔ ‪٤٢١-٤١٥‬‬
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
‫‪R Streptomycin 12‬‬
‫‪Tobramycin 13‬‬
‫‪R‬‬
‫ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﻓﻲ ﺒﻜﺘﺭﻴﺎ ﺍﻟـ ‪ K. pneumoniae‬ﺒﺘـﺭﺩﺩ‬
‫‪89 85 84 76 93 65‬‬
‫ﻋﺎﻟﻲ ﻤﻘﺎﺭﻨـﺔ ﺒﺒﻘﻴـﺔ ﻋﻭﺍﻤـل ﺍﻟﺘﺤﻴﻴـﺩ ﺍﻟﻤﺴـﺘﺨﺩﻤﺔ ﻜﺎﻟــ‬
‫‪R‬‬
‫‪I‬‬
‫‪R‬‬
‫‪I‬‬
‫‪R‬‬
‫‪R‬‬
‫‪ :R‬ﻤﻘﺎﻭﻤﺔ‪.‬‬
‫‪ :S‬ﺤﺴﺎﺴﺔ )ﺘﺸﻴﺭ ﺍﻟﻰ ﺍﻥ ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﻟﻠﺘﺤﻴﻴﺩ ‪.(%100‬‬
‫‪ :I‬ﻤﺘﻭﺴﻁﺔ ﺍﻟﺤﺴﺎﺴﻴﺔ )ﻟﻡ ﻴﺠﺭ ﺍﺨﺘﺒﺎﺭﻫﺎ(‪.‬‬
‫ﺠﺩﻭل ‪ :4‬ﺘﺄﺜﻴﺭ ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﻟﻌﺯﻻﺕ ‪K. pneumoniae‬‬
‫ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟـ ‪ SDS‬ﻓﻲ ﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ‬
‫ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﻟﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩ ﺍﻟﺫﻱ‬
‫ﺕ‬
‫ﺍﻟﻤﻀﺎﺩ ﺍﻟﺤﻴﻭﻱ‬
‫ﻴﺸﻔﺭ ﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﻀﺎﺩ )‪(%‬‬
‫‪K7 K6 K5 K4 K3 K2 K1‬‬
‫‪R‬‬
‫‪1‬‬
‫‪Ampicillin‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪2‬‬
‫‪Pepracillin‬‬
‫‪89 82 98‬‬
‫‪S‬‬
‫‪87 88 85‬‬
‫‪3‬‬
‫‪Amoxicillin‬‬
‫‪S‬‬
‫‪S‬‬
‫‪S‬‬
‫‪4‬‬
‫‪Penicillin G‬‬
‫‪96‬‬
‫‪S‬‬
‫‪99 94 92‬‬
‫‪5‬‬
‫‪Cephalexin‬‬
‫‪80 91‬‬
‫‪6‬‬
‫‪Cephalothin‬‬
‫‪I‬‬
‫‪7‬‬
‫‪Ceftazidine‬‬
‫‪I‬‬
‫‪R‬‬
‫‪98 91 92 94‬‬
‫]‪ [20‬ﻭﻫﺫﻩ ﺍﻟﺒﻜﺘﺭﻴﺎ ﺍﻟﻤﻨﺘﺠﺔ ﻟﻬﺫﻩ ﺍﻻﻨﺯﻴﻤﺎﺕ ﻋﺎﺩﺓ ﻤـﺎ ﺘﻜـﻭﻥ‬
‫ﺒﻼﺯﻤﻴﺩﺍﺘﻬﺎ ﺘﺤﻭﻱ ﻤﻭﺭﺜﺎﺕ ﺘﺸﻔﺭ ﺍﻴﻀﹰﺎ ﻟﻤﻘﺎﻭﻤـﺔ ﻤﻀـﺎﺩﺍﺕ‬
‫ﻭﺍﻟﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ ]‪ ،[21‬ﻜﻤﺎ ﻻﺤﻅ ﻋﺩﺩ ﻤﻥ ﺍﻟﺒﺎﺤﺜﻴﻥ ﺍﻥ ﺠﻤﻴـﻊ‬
‫ـﺯﻻﺕ‬
‫ﻋـــــــــــــــــــــــــــ‬
‫‪ K.pneumoniae‬ﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﻥ ﺍﺼﺎﺒﺎﺕ ﺍﻟﻤﺴﺘﺸﻔﻴﺎﺕ ﺘﺤـﻭﻱ‬
‫ﺒﻼﺯﻤﻴﺩ )‪ (87kb‬ﻭﺍﻥ ﻤﻘﺎﻭﻤﺔ ﺍﻟﺒﺘﺎﻻﻜﺘﺎﻡ ﻭﺍﻻﻤﻴﻨﻭﻜﻼﻴﻜﻭﺴـﺎﻴﺩ‬
‫ﻭﺍﻟﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﺘﻔﻘﺩ ﺒﻌﺩ ﺘﺤﻴﻴﺩ ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﻋﻥ ﻁﺭﻴﻕ ﺍﻟﻤﻌﺎﻤﻠﺔ‬
‫‪87 89 83‬‬
‫‪I‬‬
‫ﺒﺎﻟـ‪ Acridine orange‬ﻤﻤﺎ ﻴﺩل ﻋﻠﻰ ﺍﻥ ﻤﻭﺭﺜﺎﺘﻬﺎ ﻤﺤﻤﻭﻟـﺔ‬
‫‪92‬‬
‫ﻋﻠﻰ ﺍﻟﺒﻼﺯﻤﻴﺩ ]‪ .[17‬ﻭﻭﺠـﺩ ﺍﻥ ﺍﻟﻌﺩﻴـﺩ ﻤـﻥ ﺒﻜﺘﺭﻴـﺎ ‪K.‬‬
‫‪90 87 75 70‬‬
‫‪I‬‬
‫‪S‬‬
‫‪S‬‬
‫‪R Ciprofloxacin 8‬‬
‫‪I‬‬
‫‪R 15 R‬‬
‫‪R‬‬
‫‪I‬‬
‫‪S‬‬
‫‪S‬‬
‫‪92 86 85 82‬‬
‫‪S‬‬
‫‪R Erythromycin 10‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪85 Gentamycin 11‬‬
‫‪S‬‬
‫‪86 91 90‬‬
‫‪S‬‬
‫‪95‬‬
‫‪R Streptomycin 12‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪R‬‬
‫‪I‬‬
‫‪91‬‬
‫‪S‬‬
‫‪92 90 86‬‬
‫‪S‬‬
‫‪Tobramycin 13‬‬
‫ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ‪ R‬ﻋﻥ ﻁﺭﻴﻕ ﺍﻨﺘﺎﺠﻬﺎ ﻻﻨﺯﻴﻤـﺎﺕ ﺍﻟﺒﺘﺎﻻﻜﺘـﺎﻤﻴﺯ‬
‫‪S‬‬
‫‪90 86 89 92‬‬
‫‪9‬‬
‫ﺍﻟﺒﻴﺘﺎﻻﻜﺘﺎﻡ ﺍﻟﻰ ﺍﻥ ﺼﻔﺔ ﻤﻘﺎﻭﻤﺔ ﻫﺫﻩ ﺍﻟﻤﻀﺎﺩﺍﺕ ﻤﺤﻤﻭﻟﺔ ﻋﻠـﻰ‬
‫‪S‬‬
‫‪I‬‬
‫‪Tetracyilin‬‬
‫ﻴﻌﻭﺩ ﺤﺩﻭﺙ ﺍﻟﺘﺤﻴﻴﺩ ﻓﻲ ﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﻟﻤﺠﻤﻭﻋـﺔ‬
‫ـﻭﺒﺭﻴﻡ‬
‫ـﻭﻨﺯ‪ ،‬ﺍﻟﺘﺭﺍﻤﻴﺜـ‬
‫ـﺎﻴﺩ‪ ،‬ﺍﻟﻜﻭﻴﻨﻭﻟـ‬
‫ﺍﺨ ـﺭﻯ ﻜﺎﻷﻤﻴﻨﻭﻜﻼﻴﻜﻭﺴـ‬
‫ﺭﻗﻡ ﻋﺯﻟﺔ ‪K. pneumoniae‬‬
‫‪R‬‬
‫ـ‪ Novobiocin‬ﻭﺍﻟـ‪.[19] Ethidium bromide‬‬
‫‪R‬‬
‫‪I‬‬
‫‪ :R‬ﻤﻘﺎﻭﻤﺔ‪.‬‬
‫‪ :S‬ﺤﺴﺎﺴﺔ )ﺘﺸﻴﺭ ﺍﻟﻰ ﺍﻥ ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﻟﻠﺘﺤﻴﻴﺩ‪.(% 100‬‬
‫‪ :I‬ﻤﺘﻭﺴﻁﺔ ﺍﻟﺤﺴﺎﺴﻴﺔ )ﻟﻡ ﻴﺠﺭ ﺍﺨﺘﺒﺎﺭﻫﺎ(‪.‬‬
‫ﻴﺘﻀﺢ ﻤﻥ ﺍﻟﺠﺩﻭﻟﻴﻥ ‪ 3‬ﻭ‪ 4‬ﺍﻥ ﺍﺴﺘﺨﺩﺍﻡ ﺍﻟــ ‪Acridine‬‬
‫‪ orange‬ﻭﺍﻟـ ‪ SDS‬ﺍﺩﻯ ﺍﻟﻰ ﺤﺩﻭﺙ ﺘﺤﻴﻴـﺩ ﻓـﻲ ﻤﻘﺎﻭﻤـﺔ‬
‫ﺍﻟﻌــﺯﻻﺕ ﺍﻟﺒﻜﺘﻴﺭﻴــﺔ ﻟﻠﻤﻀــﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴــﺔ ﺒﺒﺭﺍﺴــﻴﻠﻴﻥ‪،‬‬
‫ﺍﻤﻭﻜﺴﻴﺴﻴﻠﻴﻥ‪ ،‬ﺒﻨﺴﻠﻴﻥ ﺝ‪ ،‬ﺴﻴﻔﺎﻟﻴﻜﺴﻴﻥ‪ ،‬ﺴﻴﻔﺎﻟﻭﺜﻴﻥ‪ ،‬ﺴـﻴﻔﺘﺎﺯﺩﻴﻡ‪،‬‬
‫ﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ‪ ،‬ﺠﻨﺘﺎﻤﺎﻴﺴﻴﻥ‪ ،‬ﻭﺘﻭﺒﺭﺍﻤﺎﻴﺴﻴﻥ ﻓﻲ ﺤﻴﻥ ﻟـﻡ ﻴﺤـﺩﺙ‬
‫ﺘﺤﻴﻴﺩ ﻟﻤﻘﺎﻭﻤـﺔ ﺍﻟﻤﻀـﺎﺩﺍﺕ ﺍﻤﺒﻴﺴـﻴﻠﻴﻥ‪ ،‬ﺴﺒﺭﻭﻓﻠﻭﻜﺴﺎﺴـﻴﻥ‪،‬‬
‫ﺍﺭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻭﺴﺘﺭﺒﺘﻭﻤﺎﻴﺴﻴﻥ‪ .‬ﻭﻴﻼﺤﻅ ﻭﺠﻭﺩ ﺘﺸﺎﺒﻪ ﻓﻲ ﻓﻘﺩﺍﻥ‬
‫ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻋﺎﻤﻠﻲ ﺍﻟﺘﺤﻴﻴﺩ ﺍﻻ ﺍﻥ ﻤﺎﺩﺓ ﺍﻟــ‬
‫‪ SDS‬ﺍﻜﺜﺭ ﻜﻔﺎﺀﺓ ﻓﻲ ﺍﺤﺩﺍﺙ ﺍﻟﺘﺤﻴﻴﺩ ﻤﻥ ﻤﺎﺩﺓ ﺍﻟـ ‪Acridine‬‬
‫‪orange‬ﺤﻴﺙ ﺍﻅﻬﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﻓﻘـﺩﺍﻥ ﺍﻟﻤﻘﺎﻭﻤـﺔ ﻟﻠﻤﻀـﺎﺩﺍﺕ‬
‫‪ pneumoniae‬ﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﻥ ﻋﻴﻨﺎﺕ ﺍﻟﺒﻭل ﺍﻅﻬﺭﺕ ﺍﺴـﺘﺠﺎﺒﺔ‬
‫ﻗﻠﻴﻠﺔ ﻟﻤﻀﺎﺩ ﺍﻟﺴﻴﻔﻭﺘﺎﻜﺴﻴﻡ ﻭﻫﺫﻩ ﺍﻟﻌﺯﻻﺕ ﺘﺤﻤل ﺒﻼﺯﻤﻴﺩ ﻴﺸﻔﺭ‬
‫ﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﺘﺘﺭﺍﺴﺎﻴﻜﻠﻴﻥ ﻭﺍﻟﺴﻴﻔﻭﻜﺴﻴﺘﻴﻥ ]‪ .[22‬ﺍﻥ ﻋﺩﻡ ﺤـﺩﻭﺙ‬
‫ﺍﻟﺘﺤﻴﻴﺩ ﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻤﺒﻴﺴﻠﻴﻥ ﻭﺴﺘﺭﺒﺘﻭﻤﺎﻴﺴﻴﻥ ﺠﺎﺀ ﻤﺘﻔﻘﹰﺎ‬
‫ﻤﻊ ﻤﺎ ﺘﻭﺼل ﺍﻟﻴﻪ ﺒﻌﺽ ﺍﻟﺒﺎﺤﺜﻴﻥ ﻓـﻲ ﺍﺤـﺩﻯ ﺍﻟﻤﺴﺘﺸـﻔﻴﺎﺕ‬
‫ﺍﻟﺒﺎﻜﺴﺘﺎﻨﻴﺔ ﻤﻥ ﺍﻥ ﺼﻔﺔ ﻤﻘﺎﻭﻤﺔ ﻫﺫﻩ ﺍﻟﻤﻀﺎﺩﺍﺕ ﻓـﻲ ﺒﻜﺘﺭﻴـﺎ‬
‫‪ K. pneumoniae‬ﺍﻟﻤﻌﺯﻭﻟﺔ ﻤﻥ ﻋﻴﻨﺎﺕ ﻤﺨﺘﻠﻔـﺔ ﻟﻤﺭﻀـﻰ‬
‫ﺭﺍﻗﺩﻴﻥ ﻓﻲ ﺍﻟﻤﺴﺘﺸﻔﻰ ﺘﻜﻭﻥ ﻤﺤﻤﻭﻟﺔ ﻋﻠﻰ ﺍﻟﻜﺭﻭﻤﻭﺴﻭﻡ ﻭﻟـﻴﺱ‬
‫ﺍﻟﺒﻼﺯﻤﻴﺩ ﻭﺫﻟﻙ ﺒﻌﺩ ﺍﺠﺭﺍﺀ ﺍﻟﺘﺤﻴﻴﺩ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟــ ‪Acridine‬‬
‫‪.[23] orange‬‬
‫ﺘﺸﻴﺭ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻟﺘﻲ ﺤﺼﻠﻨﺎ ﻋﻠﻴﻬﺎ ﺍﻟﻰ ﻋﺩﻡ ﺤﺩﻭﺙ ﺘﺤﻴﻴﺩ ﻟﻤﻘﺎﻭﻤﺔ‬
‫ﺍﻟﺴﺒﺭﻭﻓﻠﻭﻜﺴﺎﺴﻴﻥ ﻓﻲ ﺤﻴﻥ ﺍﺸﺎﺭﺕ ﺩﺭﺍﺴﺎﺕ ﺍﻟـﻰ ﺍﻥ ﺒﻜﺘﺭﻴـﺎ‬
‫‪ K. pneumoniae‬ﺘﺤﻭﻱ ﺒﻼﺯﻤﻴﺩﺍﺕ ﻓﻴﻬﺎ ﻤﻭﺭﺜﺎﺕ ﻤﺴـﺅﻭﻟﺔ‬
‫ﻋﻥ ﺍﻟﺘﺸﻔﻴﺭ ﻟﻤﻘﺎﻭﻤﺔ ﻤﻀﺎﺩﺍﺕ ﺍﻟﻜﻭﻴﻨﻭﻟﻭﻨﺯ ﻜﻤﺎ ﻟﻭﺤﻅ ﻫﺫﺍ ﻓـﻲ‬
‫ﺍﻟﻭﻻﻴﺎﺕ ﺍﻟﻤﺘﺤﺩﺓ ﺍﻻﻤﺭﻴﻜﻴﺔ ]‪ ،[24‬ﻭﺫﻜﺭ ﻭﺠﻭﺩ ﺍﺭﺘﺒﺎﻁ ﻗﺭﻴـﺏ‬
‫ﺒﻴﻥ ﺍﻨﺘﺎﺝ ﺍﻨﺯﻴﻤﺎﺕ ‪ ESBL‬ﻭﻤﻘﺎﻭﻤﺔ ﺍﻟﺴﺒﺭﻭﻓﻠﻭﻜﺴﺎﺴـﻴﻥ ﻓـﻲ‬
‫ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺴﻼﻻﺕ ﺍﻟـ ‪ ،[25] K. pneumoniae‬ﺍﻤﺎ ﺒﺎﻟﻨﺴﺒﺔ‬
‫ﻟﻠﻤﻀﺎﺩ ﺍﺭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻓﺎﻥ ﻋﺩﻡ ﺤﺩﻭﺙ ﺘﺤﻴﻴﺩ ﻟﻤﻘﺎﻭﻤﺘﻪ ﻗﺩ ﻴﻌﺯﻯ‬
‫ﺍﻟﻰ ﻭﺠﻭﺩ ﺍﻟﺼﻔﺔ ﺍﻟﻤﺴﺅﻭﻟﺔ ﻋﻥ ﻤﻘﺎﻭﻤﺘﻪ ﻋﻠﻰ ﻨﻭﻉ ﺍﺨﺭ ﻤـﻥ‬
‫ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠـ ‪ SDS‬ﻜﺎﻨﺕ ﺒﻤﺩﻯ ‪ %100 –70‬ﺍﻤﺎ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻌﺎﻤل‬
‫ﺍﻟﺒﻼﺯﻤﻴﺩﺍﺕ ﻏﻴﺭ ﺍﻟﻨﻭﻉ ‪.R‬‬
‫ﺍﻻﻜﺭﺩﻴﻥ ﻓﻜﺎﻨﺕ ‪ ،%100 – 28‬ﻭﺘﺘﻔﻕ ﻫﺫﻩ ﺍﻟﻨﺘﻴﺠﺔ ﻤـﻊ ﻤـﺎ‬
‫ﺍﻟﻤﺼﺎﺩﺭ‬
‫ﺍﺸﺎﺭ ﻟﻪ ﺍﻟﺒﺎﺤﺜﻭﻥ ﻓﻲ ﺩﻭﺭ ﺍﻟـ ‪ SDS‬ﻜﻤﺎﺩﺓ ﺍﻜﺜﺭ ﺘـﺄﺜﻴﺭﹰﺍ ﻓـﻲ‬
٤٢١-٤١٥ ‫ ﺍﻟﺼﻔﺤﺔ‬،٢٠١٠ ،٣‫ ﺍﻟﻌﺩﺩ‬،٥١ ‫ ﺍﻟﻤﺠﻠﺩ‬،‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‬
12. Jabeen, K.; Zafar, A. and Hasan, R. 2005.
Frequency and Sensitivity pattern of
extended spectrum beta – lastamsae
producing isolates in atertiary care hospital
Laboratory of Pakistan. J. Pak. Med. Assoc.
10:436– 39.
13. Mathur, P., Kapil. A., Das. B. and Dhawan.
B. 2002. Prevalence of extended spectrum
beta–lactamase producing gram negative
bacteria in a tertiary car hospital. Ind. J.
Med. Res. 115: 153 – 157.
14. Yah, S.C.; Eghafona, N.O.; Enabulele, I.O.
and Aluyil, H.S.A. 2006. Ampicillin usage
and Ampicillin resistant (Amer) plasmids
mediated Escherichia coli isolated from
diarrheagenic patients attending some
teaching hospital in Nigeria. Shiraz Emedical Journal. 7(4):4–18.
15. Yah, S.C.; Eghafona, N.O.; Oranusi, S. and
Abouo, A.M. 2007. Wide spread plasmid
resistance genes among proteus species in
diabetic wounds of patients in the Ahmadu
Bello university teaching hospital (ABUTH)
Zaria. African Journal of Biotechnology.
6(15):1757 – 1762.
16. Inkhorn, A.F.; Neugauser, M.M.; Bearden,
D.T.; Quinn, J. P. and penland, S.L. 2002.
Extended spectrum beta – lactamases:
frequency, risk factors and outcomes.
Pharmocotherapy. 22: 14–20.
17. Araque, M.; Nieves, B.; Laurehi, L. and
Rossolini, G.M. 2000. Molecular basis of
extended – spectrum beta – lactamase
production in nosocomial isolates of K.
pneumoniae. from Meridan, Venzuella. Int.
J. Antimicrob. Agents. 15(1): 37–42.
18. Jacobs, R.A; Guglielmo, B.J. 2005. Antiinfective Chemotherapeutic and Antibiotic
Agents. In: Tierney, L.M. McPhee, S.J,
Papadakis M.A, eds. Current Medical
Diagnosis and Treatment. 44th edition. New
York, Lange Medical Books/ McGraw-Hill,
pp.15-31.
19. El-Mansi, M.; Karen, J.A.; Craig, A.I.;
Inche, L.K.; Linda, K. K. and David, J.P.
2000. Isolation and curing of the Klebsiella
species large indigenous plasmid using SDS.
Microbiology. 151(3):201–208.
20. Jacoby, G.A. 1994. Properties of plasmids
responsible for production of extended
spectrum beta–lactamase. Eur. J. Clin.
Infect. 13(51): 2 – 11.
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
1. Neu, L. H. 1992. The Crisis in antibiotic
resistance. Science. 257:1054 – 1073.
2. Hajarnis, S. 1996. Suspected urinary tract
infections: Identification of microorg-anisms
and sensitivity to antibiotics in Seychelles.
Ind. Path. Microbiol. 36(2): 114 – 123.
3. Jacoby, G. A. and Sutton. L. 1991. Properties
of plasmids responsible for production of
extended – spectrum beta – actamases.
Antimicrob. Agents Chemother 35: 164 – 189.
4. Steward, C.D.; Rasheed, J.K.; Hubert, S.K.;
Biddle, J.W. and Raney, P.M. 2001.
Characterization of clinical isolates of
Klebsiella pneumoniae from 19 laboratories
using the National Committees for Clinical
Laboratory Standards, extended spectrum
beta–lactamase detection methods. J. Clin.
Microbial. 39: 2864 – 2872.
5. Mickelsen, P.A.; Plorde, J.J.; Gordon, K.P.;
Hargisis, C. and Muclure, J. 1985. Instability
of antibiotics resistance in a strain of
Staphylococcus epidermidis isolated from an
outbreak of prosthetic valve endocarditis. J.
Infect. Dis. 152:50–58.
6. Holt, G.T.; Krie, R.N.; Sneath, P.H.A.; Staley,
T.J. and Williams, T.S. 1994. Bergey,s
Manual of Determinative Bacteriology. 9th
edition. (Williams and Wilkins, Baltimore,
Md., USA). pp.176- 211.
7. Collee, J.G. and Marr, W. 1996. Culture of
bacteria. In: Mackie and Maccarthey.
Practical medical microbiology. (Eds. Collee,
J.G., Fraser. A.G., Marmion. B.P. and
Simmon. A.) 14th ed., Churchill Livingstone,
New York, pp.113–129.
8. Yan, J.J.; Ko, W.C.; Tsai, S.H.; Wu, H.M. and
Wu, J.J. 2001. Outbreat of infection with
multi-drug resistant Klebsiella preumoniae
carrying bla (IMP-8) in a university medical
centre in Taiwan. J. Clin. Microbial. 39: 44334439.
9. Trevors, J.T. 1986. Plasmid curing in bacteria.
FEMS microbiology reviews. 32:1٥٧ – 1٩٩.
10. Marcelo, E.T.; Luis, A.A. and Jorge, H.C.
1993. Virulence plasmids. In: Plasmids: A
partical approach (Ed.): K.G. Hardy.
Oxford university press, Oxford. pp. 5– 118.
11. National Committee for Clinical Laboratory
Standards. 1999. Performances standards
for antimicrobial susceptibility testing. 9th
ed., informational supplemented. Wayne,
P.A.: National Committee for Clinical
Laboratory Standards.
٤٢١-٤١٥ ‫ ﺍﻟﺼﻔﺤﺔ‬،٢٠١٠ ،٣‫ ﺍﻟﻌﺩﺩ‬،٥١ ‫ ﺍﻟﻤﺠﻠﺩ‬،‫ﺍﻟﻤﺠﻠﺔ ﺍﻟﻌﺭﺍﻗﻴﺔ ﻟﻠﻌﻠﻭﻡ‬
indigenous Klebsiella. Puk J. Bot.
35(2):243– 248.
24. Wang, M.; Sahm, M.F.; Jacoby, G.A. and
Hooper, D.C. 2004. Emerging plasmid–
mediated quinolones resistance associated
with the qnr gene in Klebsiella pneumoniae
clinical isolates in the United States.
Antimicrob. Agents. Chemother. 48(4):
1295–1299.
25. Paterson, D.L.; Mulazimoglu, L. and
Casellas, J.M. 2000. Epidemiology of
ciprofloxacin resistance and it's relationship
to extended spectrum beta–lactamase
production in Klesiella pneumoniae. Clin.
Infect. Dis. 30:473–478.
‫ﻓﺭﺝ ﻭﻏﻨﻴﻤﺔ‬
21. Nathisuwan, S.; Burgess, D.S. and Lewis,
J.S. 2001. Extended spectrum beta–
lactamase: epidemiology, detection and
treatment. Pharmacotherapy. 21:920 – 926.
22. Shahid, M.; Malik, A.; Akram, M.;
Agrawal, L.M. and Khon, A.U. 2008.
Prevalent phenotypes and antibiotics
resistance in Eschericnia coli and Klebsiella
pneumoniae at an Indian tertiary care
hospital: plasmid– mediated Cefoxitin
resistance. Int. J. Infect. Dis. 12(3): 256 –
264.
23. Sheikh, A.R.; Afsheen, A.; Sadia, K. and
Abul Wanab, A. 2003. Plasmid born
antibiotic
resistance
factors
among